Latest News and Press Releases

Chemomab announces late-breaking oral presentation of CM-101 Phase 2 results in primary sclerosing cholangitis patients at 2024 AASLD The Liver Meeting

Chemomab will participate in the ROTH Healthcare Opportunities Conference in NYC on Oct 9 and the Maxim Healthcare Virtual Summit on Oct 16 at 9am ET.

Chemomab will be presenting at the HC Wainwright Global Investment Conference and the HBM Biopharma Summit in September

Ph 2 PSC data showed safety/activity supporting advancing CM-101 to Ph 3. New financing extends cash runway to early 2026. 2 milestones on track for 1Q25.

Chemomab will report its second quarter 2024 financial results and provide a business update on August 21, 2024 at 7:00am ET.

Chemomab closed a $10 million PIPE financing that included new and existing top tier investors and extends the cash runway through the beginning of 2026

Chemomab has regained full compliance with the Nasdaq minimum bid price rule

Chemomab announced a $10 million PIPE that enables the company to extend its cash runway until early 2026, well past 2 upcoming milestones in early 2025.

Chemomab reported positive topline results from Ph 2 trial assessing CM-101 in PSC. Achieved safety endpoint and improved wide range of secondary endpoints

New publication confirms the role of CCL24 in primary sclerosing cholangitis and the potential of CM-101 to impact PSC disease progression and severity.